Lineage Cell Therapeutics (LCTX) Return on Capital Employed Growth (5y) (2016 - 2026)

Lineage Cell Therapeutics (LCTX) Return on Capital Employed Growth (5y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Lineage Cell Therapeutics 267.08 Mn 203.18 Mn 1.73 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -1,323.00
Dec 31, 2025 -1,375.00
Sep 30, 2025 -1,604.00
Jun 30, 2025 -1,194.00
Mar 31, 2025 767.00
Dec 31, 2024 805.00
Sep 30, 2024 444.00
Jun 30, 2024 -77.00
Mar 31, 2024 346.00
Dec 31, 2023 276.00
Sep 30, 2023 266.00
Jun 30, 2023 1,387.00
Mar 31, 2023 679.00
Dec 31, 2022 -37.00
Sep 30, 2022 -1,968.00
Jun 30, 2022 -1,783.00
Mar 31, 2022 -783.00
Dec 31, 2021 -324.00
Sep 30, 2021 3,740.00
Jun 30, 2021 6,929.00